ValuEngine upgraded shares of Sierra Oncology (NASDAQ:SRRA) from a hold rating to a buy rating in a research note released on Thursday morning.
Separately, Zacks Investment Research lowered shares of Sierra Oncology from a hold rating to a sell rating in a report on Thursday, October 4th.
Shares of Sierra Oncology stock opened at $1.83 on Thursday. The firm has a market capitalization of $136.05 million, a price-to-earnings ratio of -2.18 and a beta of 1.73. Sierra Oncology has a 52-week low of $1.48 and a 52-week high of $4.09.
Sierra Oncology (NASDAQ:SRRA) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). On average, equities research analysts forecast that Sierra Oncology will post -0.71 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of SRRA. JPMorgan Chase & Co. boosted its stake in shares of Sierra Oncology by 91,592.6% in the 1st quarter. JPMorgan Chase & Co. now owns 221,896 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 221,654 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Sierra Oncology by 171.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 752,191 shares of the biotechnology company’s stock valued at $1,557,000 after purchasing an additional 475,288 shares in the last quarter. UBS Group AG acquired a new stake in shares of Sierra Oncology in the 1st quarter valued at $111,000. Millennium Management LLC boosted its stake in shares of Sierra Oncology by 86.6% in the 1st quarter. Millennium Management LLC now owns 2,280,430 shares of the biotechnology company’s stock valued at $4,720,000 after purchasing an additional 1,058,574 shares in the last quarter. Finally, Fred Alger Management Inc. acquired a new stake in shares of Sierra Oncology in the 2nd quarter valued at $246,000. Institutional investors own 64.21% of the company’s stock.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Featured Article: Average Daily Trade Volume – What It Means In Stock Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.